Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL: one-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
metformin 2 endocrinologydiseasesdrugs
Insulin 2 endocrinologydiseasesdrugs

There are not enough annotations found in this document to create the proximity graph.


Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Insulin 3297 informationThis study was sponsored by Sanofi.INTRODUCTION1 Insulin is recommended for the management of type 2 diabetes (T2DM) once glycaemic targets can no longer be
Insulin 15677 time, was either higher or comparable in the Gla‐300 compared with the Gla‐100 group (Table S2). Insulin dose3.7During the 12‐month treatment period, the daily basal insulin dose increased in both treatment
metformin 5730 with ≥42 U/d of either Gla‐100 or NPH insulin, together with mealtime insulin with or without metformin , for at least 1 year.9 In EDITION 2, participants had at least 6 months on basal insulin treatment
metformin 21320 previously observed in people treated with glargine compared with people treated with NPH insulin added to metformin , with an initial HbA1c of ~9.5 % (80 mmol/mol).19 Another explanation may be related to the evening
Select Disease Character Offset Disease Term Instance

You must be authorized to submit a review.